Vaxart Inc (VXRT)
$5.24
0. (0.00%)
VXRT Stock Quote Delayed 30 Minutes
Vaxart: Oral Covid-19 Vaccine Is Interesting, But Questions Linger
VXRT stock is more than a Covid-19 meme trade. But is there enough fundamentals there to support an investment heading into 2022?
11 Best Stocks to Buy for 2022
He found Apple at $1.49... Oracle at $0.51... Amazon at $46. Now, investing legend Louis Navellier is revealing his Top 11 Stocks for 2022 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
657.60M
PE Ratio
-9.70
EPS
-0.54
Volume (Avg. Vol.)
Day's Range
-
52-Week Range
$4.86 - $24.90
Dividend & Yield
N/A (N/A)
VXRT Stock Predictions, Articles, and Vaxart Inc News
Why Investing in VXRT Stock is a Coin Flip
Vaxart is a gamble for biotechnology investors, with its upside too dependent on the approval of an oral vaccine.
Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today
Today, vaccine stocks are taking a massive hit as investors price in the potential effect of oral medications for Covid-19 on this sector.
Vaxart Traders Should Not Dismiss the Vaccine Maker’s Momentum
The recently range-bound price action of VXRT stock doesn't reflect the progress that Vaxart is making against Covid-19.
It’s Time to Start Thinking Seriously About Vaxart
While VXRT stock is risky due to underlying clinical challenges, the evolving nature of Covid-19 makes it worth consideration.
Vaxart Stock Is One Vaccine Also-Ran Worth Another Look
If you're looking to wager on a vaccine long-shot, place your bet on VXRT stock.
Is Vaxart Stock Really Worth a Shot?
VXRT stock still has hope as Vaxart is developing modern rDNA vaccines in pill form (including a Covid-19 vaccine), aiming to overcome needle challenges.
Longshot Covid Play Vaxart Stock Is Too Risky at These Prices
Vaxart got approval Aug. 2 for a Phase II trial for its oral Covid-19 vaccine. VXRT stock has gained 22% since. Should you buy on momentum?
Vaxart Is Another Risky Biotech Stock to Avoid Right Now
VRXT stock is highly overvalued. Investors are holding out for its Covid-19 vaccine, but it may not be approved in time to boost shares.
The Delta Variant Is a Shot in the Arm for Vaxart’s Pill Vaccine
The Delta Covid variant gives Vaxart new life with its oral vaccine and could boost VRXT stock. VXRT stock is worth over 30% more at $13.00 if its Covid pill works, according to sell-side analysts.
Vaxart Stock Probably Isn’t Worth the Risk as It Pushes Higher
Vaxart’s oral recombinant vaccines are an interesting approach. Whether they do anything for VXRT stock remains to be seen.
The Bull Thesis for VXRT Stock is Questionable at Best
If Vaxart were to fulfill its promise a lot would have to transpire in its favor. Here's why you shouldn't expect that to happen.
VXRT Stock: The Big FDA News Sending Vaxart Shooting Higher Today
VXRT stock is bulking up today. The company is getting approval from the FDA regarding its Covid vaccine, allowing for further research.
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
So what did the stock market do today? All eyes were on hard-hit Nikola stock and growing interest in mental health startups.
Vaxart Stock Has Built-In Value Well Beyond Its Covid Pill
You can buy VXRT stock for the company's tablet-based Covid-19 vaccine, and hold it for Vaxart's other clinical breakthroughs.
Vaxart Is Gaining Relevance, But Its Future Is Still Uncertain
Vaxart may have a second chance at prominence with its Covid-19 vaccine pill. But VXRT stock is still a largely speculative buy.
Don’t Count on a Covid-19 Boost for Vaxart
VXRT stock remains a speculative bet as the company's chance to develop an oral Covid-19 vaccine grows slimmer every day.
New Developments Have Made Vaxart Stock So Much More Attractive
Vaxart recently made a licensing deal, and two research firms issued upbeat assessments of the company, making me more upbeat on VXRT stock.
Watch Out for a Selloff in Vaxart Stock
Vaxart needs a Covid-19 vaccine approved and selling on the market before the established mega-cap names take all the sales.
Vaxart Stock Could Make Another Big Return in the Future
VXRT stock is known to be a fast mover. Any piece of good news could prove to be a multi-bagger for investors who take an early position.
